Newrange Gold Corp. (NRGOF)(NRG:CA) – On the Right Path

Posted on March 10, 2022 by Admin

Thursday, March 10, 2022

Newrange Gold Corp. (NRGOF)(NRG:CA)
On the Right Path

As of April 24, 2020, Noble Capital Markets research on Newrange Gold is published under ticker symbols (NRGOF and NRG:CA). The price target is in USD and based on ticker symbol NRGOF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.

Newrange Gold Corp is an exploration stage company focused on acquiring and exploring exploration and evaluation assets in Colombia and the United States. The Company operates in a single reportable operating segment-the acquisition, exploration, and development of mineral properties. Some of the projects acquired by the company are Pamlico gold project in Nevada and Rocky mountain project in Colorado. The company also holds an interest in the Yarumalito property, El Dovio property and Anori property in Colombia.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Drilling at North Birch. Newrange commenced drilling in February at the North Birch project in the Birch-Uchi Greenstone Belt in northwestern Ontario, Canada with approximately 2,000 meters of drilling planned. Once completed, the rig may be moved to the nearby past-producing Argosy gold mine to test the depth of known veins below historic mine workings, along with the continuity of other veins.

Geophysical surveys lead the way. In April 2021, Newrange completed an induced polarization (IP) survey over the eastern portion of the North Birch project area covering the main target horizon. The survey revealed several well-defined chargeability anomalies which are being targeted for drilling and coincide with the target horizon along the limb of the sheared and folded iron formation. A LiDAR …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

Kelly Services (KELYA) – Re-allocation of Capital Has Begun; Acquiring RocketPower

Posted on March 10, 2022 by Admin

Thursday, March 10, 2022

Kelly Services (KELYA)
Re-allocation of Capital Has Begun; Acquiring RocketPower

Kelly Services Inc is a provider of workforce solutions and consulting and staffing services. The company’s operations are divided into three business segments namely Americas Staffing, Global Talent Solutions (“GTS”) and International Staffing. It provides staffing solutions through its branch networks in Americas and International operations and also provides a suite of innovative talent fulfilment and outcome-based solutions through GTS segment. Americas Staffing generates maximum revenue from its operations.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Redeploying APAC Capital. In its first move since the February announcement of the sale of the majority of its APAC assets, Kelly Services is acquiring fast-growing RocketPower, a leading provider of Recruitment Process Outsourcing (RPO) and other outsourced talent solutions. Management described the business as “high-margin, high-growth assets,” although terms of the deal were not disclosed.

Who Is RocketPower? Founded in 2016 by Silicon Valley veteran Mat Caldwell, RocketPower is a leading provider of RPO and other outsourced talent solutions. RocketPower’s customers include rapidly scaling U.S. tech companies known for disrupting industries and changing the world. In 2021, RocketPower generated $28 million of revenue and anticipates triple digit growth in 2022 …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Item 9 Labs (INLB) – Begins Capital Raise; Closes on First Dispensary Acquisition

Posted on March 10, 2022 by Admin

Thursday, March 10, 2022

Item 9 Labs (INLB)
Begins Capital Raise; Closes on First Dispensary Acquisition

Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The award-winning Item 9 Labs brand specializes in best-in-class products and user experience across several cannabis categories. The company also offers a unique dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. Item 9 Labs brings the best industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation. The veteran management team combines a diverse skill set with deep experience in the cannabis sector, franchising, and the capital markets to lead a new generation of public cannabis companies that provide transparency, consistency, and well-being. Headquartered in Arizona, the company is currently expanding its operations space by 650,000+ square feet on its 50-acre site, one of the largest properties in Arizona zoned to grow and cultivate flower. For additional information, visit item9labscorp.com.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Capital Raise. Yesterday, Item 9 Labs announced the launch of its global, streamlined Regulation A, Tier 2 public offering for unaccredited and accredited investors. The Company is offering 28 million units, each comprised of one share and one-half of one warrant. Upon the exercise of all warrants, the offering has maximum proceeds of $67.2 million. The offering price is $1.40 per unit and the exercise price is $2.00 per warrant share.

To Fuel Growth. The net proceeds of the offering will be used to fuel growth. Proceeds will be used to fund the Company’s retail dispensary acquisition strategy, for the potential acquisition of additional cultivation properties, and for working capital purposes. Assuming funds are raised, we believe this would be a net positive for Item 9 Labs as the additional capital would enable an acceleration …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

The Melt Value of a Nickel Coin

Posted on March 10, 2022November 4, 2024 by Admin


  Image: Dave (Flickr)

Digital Currency (USD Coin) Could Save the US a Mint

It cost more in materials for the US Mint to make a nickel than 5 cents. Other coins also cost more to produce than their face value. It’s worth considering that it would cost almost nothing to create five cents worth of a US Central Bank Digital Currency (CBDC). While this isn’t the likely reason the US and other nations are exploring
CBDCs, it may add to the benefits if metals prices keep rising. Below we explore the current rate and melt value of the US five-cent piece.

The spike in raw nickel prices, even before the recent short-squeeze, has lifted the value of the metal in the coin bearing the image of Jefferson. The make-up of recent nickels is 25% nickel and 75% copper.

Source: Koyfin

Nickel prices reached $100,000 per metric ton (one million grams) on the London Metal Exchange in early March before trading was halted. The metal had been trading around $25,000 a ton before the spike. At $100,000, the coin would contain about 16 cents in metal or melt value. Each nickel weighs five grams, (unintentional coincidence) and contains 1.25 grams of nickel and 3.75 grams of copper.

Source: US
Mint

At $100,000 a metric ton, the math is easy, 1.25 grams are worth 12.5 cents of nickel. As for the larger copper component, with copper trading at $10,000 a metric ton, 3.75 grams equals 3.75 cents in value.

At the end of its fiscal year, nickel was trading at $17,500 a metric ton. Including copper and other costs, a nickel costs 8.52 cents to produce. Pennies also cost more to produce, more than twice their value.

The US Mint created about 15 billion coins last year and realized about $1 billion in revenue. It is worth noting here that the US Mint prohibits the melting down of pennies and nickels for their metal value.

In its 2021 annual
report, the Mint wrote: “The unit cost for both pennies (2.10 cents) and nickels (8.52 cents) remained above face value for the 16th consecutive fiscal year. Compared to last year, FY 2021 average spot prices for nickel increased 28.1 percent to $17,503.10 per tonne, average copper prices also increased 48.2 percent to $8,676.77 per tonne, and average zinc prices increased 27.9 percent to $2,821.12 per tonne.”

Should prices continue to rise at the 2022 pace or similar to prior years, a US digital currency could help reduce the cost of coin production of the US Mint to below the face value.

Paul Hoffman

Managing Editor, Channelchek

Suggested Reading

Digital Currencies Gain Value on Biden Executive Order

Investing in the Businesses in and Around Crypto

Stay up to date. Follow us:

Release – Tonix Pharmaceuticals Announces Appointment of Jeffrey Rosenfeld PhD

Posted on March 9, 2022 by Admin

Tonix Pharmaceuticals Announces Appointment of Jeffrey Rosenfeld, Ph.D., as Executive Director, Genomics and Bioinformatics

Research, News, and Market Data on Tonix Pharmaceuticals

CHATHAM, N.J., March 09, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of Jeffrey Rosenfeld, Ph.D., as its new Executive Director, Genomics and Bioinformatics. In this role, Dr. Rosenfeld will direct Tonix’s pharmacogenomics efforts including applying artificial intelligence, genome-wide association studies and mathematical modeling techniques to the analysis of patient outcomes in Tonix’s clinical trials.

“Dr. Rosenfeld brings substantial genomics expertise to Tonix that will support our efforts in pharmacogenomics and companion diagnostics,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “As we continue to advance our pipeline and programs, Dr. Rosenfeld’s abilities and his passion for genomics will support the future success of our drug development efforts.”

“I am excited to join Tonix to lead the Company’s efforts to integrate genomics with clinical trials,” said Dr. Rosenfeld. “I look forward to working closely with the team to fully realize the potential of the Company’s deep portfolio of product candidates.”

Dr. Rosenfeld has a record of achievement in genomics and bioinformatics. Over his 15-year career in genomics, he has contributed to a wide range of biological and genetic projects, including genetic association studies of schizophrenia and clinical cancer genome sequencing. Most recently, he led an effort to investigate markers for autism in paternal sperm. For the past seven years, Dr. Rosenfeld has been an Assistant Professor of Pathology and Laboratory Medicine and the Manager of the Biomedical Informatics Shared Resource at the Rutgers Cancer Institute of New Jersey. In 2013, he founded Genome Liberty which developed tools for direct-to-consumer pharmacogenomics testing. Dr. Rosenfeld earned his B.S. in Biology and M.S. in Biotechnology from the University of Pennsylvania and a Ph.D. in Biology from New York University. He completed doctoral research at the Cold Spring Harbor Laboratory.

About Tonix Pharmaceuticals Holding Corp.

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of immunology, central nervous system (CNS) and infectious disease product candidates. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including Tonix’s lead immunology candidate TNX-1500¹, which is a humanized monoclonal antibody targeting CD40 ligand being developed for the prevention of allograft rejection and the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to start in the second half of 2022. The Company’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL², (cyclobenzaprine HCl sublingual tablets), is a small molecule drug in mid-Phase 3 development for the management of fibromyalgia, with a new Phase 3 study expected to start in the first half of 2022. TNX-102 SL is also being developed to treat Long COVID, a chronic post-COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the first half of 2022. TNX-1300³ is a biologic designed to treat cocaine intoxication that is expected to start a Phase 2 trial in the first half of 2022. Tonix’s infectious disease pipeline includes a vaccine in development to prevent smallpox, next-generation vaccines to prevent COVID-19 and an antiviral to treat COVID-19. Tonix’s lead vaccine program is TNX-801 (live horsepox virus for percutaneous administration) for preventing smallpox and monkeypox⁴. Horsepox is also the basis for Tonix’s recombinant pox vaccine (RPV) platform. Tonix’s lead vaccine candidates designed for COVID-19, TNX-1840 and TNX-1850⁵, are live virus vaccines in development based on the RPV platform. Finally, TNX-3500⁶ (sangivamycin, i.v. solution) is a small molecule antiviral drug to treat acute COVID-19 and is in the pre-IND stage of development.

¹TNX-1500 is an investigational new biologic at the pre-IND stage of development and has not been approved for any indication.
²TNX-102 SL is an investigational new drug and has not been approved for any indication.
³TNX-1300 is an investigational new biologic and has not been approved for any indication.
⁴TNX-801 is an investigational new biologic at the pre-IND stage of development and has not been approved for any indication.
⁵TNX-1840 and TNX-1850 are investigational new biologics at the pre-IND stage of development and have not been approved for any indication. TNX-1840 and TNX-1850 are designed to express the spike protein of SARS-CoV-2 from omicron and BA.2 variants, respectively, based on the experience from TNX-1800, which expresses the spike protein from the ancestral Wuhan strain.
⁶TNX-3500 is an investigational new drug at the pre-IND stage of development and has not been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission (the “SEC”) on March 15, 2021, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Contacts

Jessica Morris (corporate)
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(212) 688-9421

Olipriya Das, Ph.D. (media)
Russo Partners
olipriya.das@russopartnersllc.com
(646) 942-5588

Peter Vozzo (investors)
ICR Westwicke
peter.vozzo@westwicke.com
(443) 213-0505

Source: Tonix Pharmaceuticals Holding Corp.

Li-Ion Batteries Promising New Process

Posted on March 9, 2022 by Admin



  Image: Brookhaven Nat’l Lab (Flickr)

Toward Batteries that Pack Twice as Much Energy Per Pound

David L. Chandler | MIT News Office

In the endless quest to pack more energy into batteries without increasing their weight or volume, one especially promising technology is the solid-state battery. In these batteries, the usual liquid electrolyte that carries charges back and forth between the electrodes is replaced with a solid electrolyte layer. Such batteries could potentially not only deliver twice as much energy for their size, they also could virtually eliminate the fire hazard associated with today’s lithium-ion batteries.

But one thing has held back solid-state batteries: Instabilities at the boundary between the solid electrolyte layer and the two electrodes on either side can dramatically shorten the lifetime of such batteries. Some studies have used special coatings to improve the bonding between the layers, but this adds the expense of extra coating steps in the fabrication process. Now, a team of researchers at MIT and Brookhaven National Laboratory have come up with a way of achieving results that equal or surpass the durability of the coated surfaces, but with no need for any coatings.

The new method simply requires eliminating any carbon dioxide present during a critical manufacturing step, called sintering, where the battery materials are heated to create bonding between the cathode and electrolyte layers, which are made of ceramic compounds. Even though the amount of carbon dioxide present is vanishingly small in air, measured in parts per million, its effects turn out to be dramatic and detrimental. Carrying out the sintering step in pure oxygen creates bonds that match the performance of the best coated surfaces, without that extra cost of the coating, the researchers say.

The findings are reported in the journal Advanced Energy Materials, in a paper by MIT doctoral student Younggyu Kim, professor of nuclear science and engineering and of materials science and engineering Bilge Yildiz, and Iradikanari Waluyo and Adrian Hunt at Brookhaven National Laboratory.

“Solid-state batteries have been desirable for different reasons for a long time,” Yildiz says. “The key motivating points for solid batteries are they are safer and have higher energy density,” but they have been held back from large scale commercialization by two factors, she says: the lower conductivity of the solid electrolyte, and the interface instability issues.

The conductivity issue has been effectively tackled, and reasonably high-conductivity materials have already been demonstrated, according to Yildiz. But overcoming the instabilities that arise at the interface has been far more challenging. These instabilities can occur during both the manufacturing and the electrochemical operation of such batteries, but for now the researchers have focused on the manufacturing, and specifically the sintering process.

These discs were used for testing the researchers’ processing
method for solid-electrolyte batteries. On the left, a sample of the solid
electrolyte itself, a material known as LLPO. At center, the same material
coated with the cathode material used in their tests. At right, the LLPO
material with a coating of gold, used to facilitate measuring its electrical
properties. Credit: Pjotrs Žguns

Sintering is needed because if the ceramic layers are simply pressed onto each other, the contact between them is far from ideal, there are far too many gaps, and the electrical resistance across the interface is high. Sintering, which is usually done at temperatures of 1,000 degrees Celsius or above for ceramic materials, causes atoms from each material to migrate into the other to form bonds. The team’s experiments showed that at temperatures anywhere above a few hundred degrees, detrimental reactions take place that increase the resistance at the interface — but only if carbon dioxide is present, even in tiny amounts. They demonstrated that avoiding carbon dioxide, and in particular maintaining a pure oxygen atmosphere during sintering, could create very good bonding at temperatures up to 700 degrees, with none of the detrimental compounds formed.

The performance of the cathode-electrolyte interface made using this method, Yildiz says, was “comparable to the best interface resistances we have seen in the literature,” but those were all achieved using the extra step of applying coatings. “We are finding that you can avoid that additional fabrication step, which is typically expensive.”

The potential gains in energy density that solid-state batteries provide comes from the fact that they enable the use of pure lithium metal as one of the electrodes, which is much lighter than the currently used electrodes made of lithium-infused graphite.

The team is now studying the next part of the performance of such batteries, which is how these bonds hold up over the long run during battery cycling. Meanwhile, the new findings could potentially be applied rapidly to battery production, she says. “What we are proposing is a relatively simple process in the fabrication of the cells. It doesn’t add much energy penalty to the fabrication. So, we believe that it can be adopted relatively easily into the fabrication process,” and the added costs, they have calculated, should be negligible.

Large companies such as Toyota are already at work commercializing early versions of solid-state lithium-ion batteries, and these new findings could quickly help such companies improve the economics and durability of the technology.

The research was supported by the U.S. Army Research Office through MIT’s Institute for Soldier Nanotechnologies. The team used facilities supported by the National Science Foundation and facilities at Brookhaven National Laboratory supported by the Department of Energy.

Suggested Reading

Lithium Battery vs. Hydrogen Fuel Cell Vehicles

Lithium Prices Continue Their Ascent

EV Inflation Outpacing Traditional Cars

Is the Index Bubble Michael Burry Warned About Still Looming?

Stay up to date. Follow us:

Release – Ayala Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference

Posted on March 9, 2022 by Admin

Ayala Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference

Research, News, and Market Data on Ayala Pharmaceuticals

REHOVOT, Israel and WILMINGTON, Del., March 09, 2022 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will present at the 32^nd Annual Oppenheimer Healthcare Conference, taking place on March 15-17, 2022. The company will also participate in one-on-one investor meetings at the conference.

Details on the presentation can be found below.

32nd Annual Oppenheimer Healthcare Conference

Format:	Virtual Presentation

Date:	Tuesday, March 15, 2022

Time:	10:40 AM – 11:10 AM EDT

A webcast of the presentation will be available on the “Events and Presentations” section of the Ayala Pharmaceuticals website.

About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. AL102 is currently in a Pivotal Phase 2/3 clinical trials for patients with desmoid tumors (RINGSIDE) and is being evaluated in a Phase 1 clinical trial in combination with Novartis’ BMCA targeting agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma. For more information, visit www.ayalapharma.com.

Contacts:

Investors:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com

Ayala Pharmaceuticals:
+1-857-444-0553
info@ayalapharma.com

Release – Lifeist Portfolio Company Mikra Begins Presales of CELLF

Posted on March 9, 2022 by Admin

Lifeist Portfolio Company, Mikra, Begins Presales of CELLF™

Research, News, and Market Data on Lifeist Wellness

With a waitlist of over 40,000 subscribers, Mikra launches presale of innovative cellular therapeutic to help combat oxidative stress

TORONTO, March 09, 2022 (GLOBE NEWSWIRE) — Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: NXTTF), a health-tech company that leverages advancements in science and technology to build breakthrough companies that transform human wellness, today announced a number of business updates regarding its wholly owned U.S. subsidiary, Mikra, Cellular Sciences Inc. (“Mikra”), including the commencement of presales in the U.S. for its novel cellular therapeutic compound, CELLF™, targeted at combating oxidative stress.

“Lifeist’s U.S. portfolio company Mikra is demonstrating meaningful momentum with today’s launch of presale activities for CELLF™, founded upon clear consumer research insight,” said Meni Morim, CEO of Lifeist. “We believe that Mikra has the real potential to help accelerate Lifeist’s path to profitability and value creation for shareholders, while simultaneously improving human health and wellness, and we fully support Faraaz and the team’s plan.”

Added Faraaz Jamal, COO of Lifeist and CEO of Mikra, “We are building a different type of biological sciences company. The real health crisis is not reduced longevity. Humans are living longer, but they’re not able to enjoy those extra years because they’re plagued with many chronic issues. But it’s so hard for us to evaluate longevity or health span because it requires lifetimes. Multi-omics data is the name of the game now – we’ve entered an era of precision medicine and wellness. For every product we launch, we look at how it affects you on a cellular level by mapping what gene expression pathways are triggered, positively and negatively. That way, we know that our product is actually affecting you positively at the most microscopic level: your cells.”

Mikra, Cellular Sciences has commenced its genomic and transcriptomic clinical trials to gather evidence for CELLF™ at a molecular and cellular level.

Lifeist recognizes Mikra’s potential to help accelerate the Company’s path to profitability and increasing its total addressable markets outside of Canada, through a predominantly subscription based product pipeline, differentiated through its transparent R&D pillar that pledges rigorous clinical testing, the sharing of test result data, and launching new and improved iterations of existing products. With this unique selling point, Mikra intends to drive consumer trust and capture share of a $105 billion U.S. nutraceutical market through clear distribution pathways both online and offline.

Lifeist has approved a budgetary allocation to Mikra of up to $8.5 million for the fiscal year 2022, subject to ongoing achievement of internal milestones governing each new product, and assuming reinvestment of all anticipated Mikra profits back into Mikra.

CELLF[1] Presale Commences

With a waitlist of over 40,000 subscribers and positive feedback at levels of testing, Mikra has launched presale of its innovative cellular therapeutic CELLF to help combat oxidative stress, which may manifest in symptoms such as systemic fatigue, inflammation, and brain fog.

Monthly subscriptions at www.wearemikra.com start at US$88.00 + applicable taxes, for a 30-day supply of 10ml single-serve sachets, with sales on Amazon USA targeted to commence shortly afterward. With respect to distribution in Canada, Mikra is in the process of obtaining a Natural Product Number (NPN) from Health Canada. Subject to NPN receipt, Mikra anticipates launching a Canadian retail distribution strategy in calendar Q3 2022.

Mikra’s Data-Driven Product Pipeline

Mikra subscribes to the mentality that nutraceuticals specifically meant to affect change at a cellular level should be more akin to how software and pharmaceutical companies continually improve and upgrade their products. To do so Mikra is partnering with precision clinical partners, commencing with InVivo Biosystems, to accurately evaluate CELLF on a cellular level and to better understand, with precision and speed, which human cellular pathways relate to healthy aging and performance. This insight will fuel CELLF’s data warehouse creating a pipeline of iterative and more effective versions of CELLF. Mikra intends to share publicly complete data on all trials related to CELLF, adhering to Mikra’s brand pillar of “Transparent R&D” ensuring a changelog for all subsequent versions of CELLF.

Complementing this transparent R&D approach, Mikra is in the process of establishing a scientific advisory group, composed of distinguished physicians and medical researchers to consult on CELLF iterations and new products in development.

As part of Mikra’s marketing activities, Mikra has concurrently issued a U.S. consumer facing press release found here.

About Lifeist Wellness Inc.

Sitting at the forefront of the post-pandemic wellness revolution, Lifeist leverages advancements in science and technology to build breakthrough companies that transform human wellness. Portfolio business units include: CannMart, which operates a B2B wholesale distribution business facilitating recreational cannabis sales to Canadian provincial government control boards; CannMart Labs, a BHO extraction facility for the production of high margin cannabis 2.0 products; the CannMart.com marketplace, which provides U.S. customers with access to hemp-derived CBD and smoking accessories; Australian Vapes, the country’s largest online retailer of vaporizers and accessories; Findify, a leading AI-powered search and discovery platform; and Mikra, a biosciences and consumer wellness company seeking to develop innovative therapies for cellular health.

Information on Lifeist and its businesses can be accessed through the links below:

www.lifeist.com
www.cannmart.com
www.australianvaporizers.com.au
www.wearemikra.com

Contacts

Lifeist Wellness Inc.
Meni Morim, CEO
Matt Chesler, CFA, Investor Relations
Ph: 647-362-0390
Email: ir@lifeist.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

Forward Looking Information

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as “may”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen.

The forward-looking information contained herein, including, without limitation, statements related to Mikra’s contribution to the Company’s anticipated path to profitability and value creation for shareholders, the anticipated therapeutic benefits of Mikra’s first product CELLF™, the anticipated budget allocated to Mikra’s development and the development of its products, the establishment of a scientific advisory group and the launch of Mikra’s Canadian retail strategy in the third quarter of this calendar year are made as of the date of this news release and is based on assumptions management believed to be reasonable at the time such statements were made, including, without limitation, that: pre-clinical trials will prove successful, the Company’s previously filed application for a patent will be granted, expectations that CELLF will gain market acceptance along with the expansion of the market for nutraceutical products, expectations that the allocated budget to Mikra will be sufficient to pursue its business strategy as anticipated and that future sales of Mikra’s products through a subscription based model is the appropriate sales model to contribute to the Company’s path to profitability, Mikra will be able to attract the distinguished medical personnel it seeks to consult on iterations of CELLF™ and new products in development, Mikra will obtain a Natural Product Number from Health Canada, in a timely manner, enabling Mikra to distribute products in Canada, management’s perceptions of the Company’s standing in the online marketplace for nutraceutical and well products, Lifeist’s beliefs regarding the expected demand for nutraceutical and wellness products and the expected growth of the nutraceutical market, the timing of product availability, as well as other considerations that are believed to be appropriate in the circumstances. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation: unforeseen developments that would delay Mikra’s ability to launch CELLF as anticipated and in a timely manner, the risk that preclinical trials are not as successful as anticipated and do not demonstrate the expected therapeutic benefits and/or fail to strengthen the Company’s patent claim, the risk that the expected demand for nutraceutical products in general and those of Mikra in particular does not develop as anticipated, the failure to convert the current number of subscribers on the pre-sales waitlist to actual sales, the inability to attract qualified physicians and medical researchers to consult on product development, the failure to obtain the requisite Natural Product Number from Health Canada resulting in Mikra not being able to distribute products in Canada, unforeseen budgetary constraints, redeployment of capital and/or Mikra’s failure to meet internal milestones governing the development of any new product, regulatory risk, risks relating to the Company’s ability to execute its business strategy and the benefits realizable therefrom and risks specifically related to the Company’s operations. Additional risk factors can also be found in the Company’s current MD&A and annual information form, both of which have been filed under the Company’s SEDAR profile at www.sedar.com. Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Source: Lifeist Wellness Inc.

Release – PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter and Full Year 2021 Financial Results

Posted on March 9, 2022 by Admin

PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter and Full Year 2021 Financial Results

Research, News, and Market Data on PDS Biotech

FLORHAM PARK, N.J., March 09, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune^® and Infectimune™ T-cell activating technologies, today announced the Company will release financial results for the three- and twelve-month periods ended December 31, 2021, on Wednesday, March 23, 2022, before the market opens. Following the release, management will host a conference call to review the financial results and provide a business update.

The conference call is scheduled to begin at 8:00 AM EDT on Wednesday, March 23, 2021. Participants should dial 877-407-3088 (United States) or 201-389-0927 (International) and mention PDS Biotechnology. A live webcast of the conference call will also be available on the investor relations page of the Company’s website at www.pdsbiotech.com. After the live webcast, the event will be archived on PDS Biotech’s website for six months.

About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer and infectious disease immunotherapies based on the Company’s proprietary Versamune^® and Infectimune™ T-cell activating technology platforms. Our Versamune^®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune^® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The Company’s pipeline products address various cancers including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar) and breast, colon, lung, prostate and ovarian cancers.

Our Infectimune™ -based vaccines have demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T-cell responses including long-lasting memory T-cell responses. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Investor Contact:
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
pdsb@cg.capital

Release – electroCore Announces Changes to its Board of Directors

Posted on March 9, 2022 by Admin

electroCore Announces Changes to its Board of Directors

News and Market Data on electroCore

Julie Bruzzone Goldstein and Tricia Wilber to join the Board, adding significant marketing, media and brand strategy experience

ROCKAWAY, N.J.,
March 09, 2022 (GLOBE NEWSWIRE) —
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Julie Bruzzone Goldstein and Tricia Wilber to the company’s Board of Directors effective
March 15, 2022. The Company also announced that effective
March 4, 2022, Dr. Stephen Ondra is resigning from the Board to focus on his new role as Chief Medical Advisor at MITRE, and Michael Atieh will not be standing for re-election to the Board at the 2022 Annual General Meeting.

“Ms. Goldstein and Ms. Wilber are successful business leaders with proven track records, and I am pleased to welcome them to our Board,” said Peter Cuneo, Chairman of the Board of Directors of electroCore. “As the company continues to invest in direct-to-consumer initiatives, their breadth of knowledge and experience will add significant value as we seek to expand the reach and impact of our therapies. These appointments are great additions to our Board of Directors, and we look forward to their contributions.”

Mr. Cuneo continued, “I would like to recognize and thank Mr. Atieh and Dr. Ondra for their long service and myriad contributions to the Company. Their leadership and dedication, Mr. Atieh’s role as our previous Chairman, and both Directors’ service on various committees, have greatly advanced our business. Both Mr. Atieh and Dr. Ondra will remain available to the Company as advisors to the Chairman and CEO. We wish them continued success in their future endeavors.”

Ms. Goldstein brings to electroCore more than 30 years of leadership expertise in product, media and entertainment marketing, which spans a career in radio, television, music and theater. Ms. Goldstein’s specific expertise includes operations, sales development, advertising, and project management. She has also spearheaded many major national and international marketing campaigns. She worked as a
Broadway producer for the musical, First Date, and served in senior marketing positions, artist development and media-sales at JIVE Records, TV Guide Television Network, RCA Records,
Virgin Records and multiple radio stations. As a key player, her expertise around spending and strategic marketing techniques contributed to RCA’s turnaround. She received the Billboard Magazine’s Radio Promotion Director of the Year, Bertelsmann Key Management Award, and
Virgin Records Promotion Director of the Year. Ms. Goldstein holds a Bachelor of Arts in Communications and Social Welfare from
California State University at Chico.

During her distinguished career, Ms. Wilber has been a Chief Marketing Officer, global business strategist, and board member who delivers organizational and cultural transformation for branding. She is a pioneer in new franchise models and branded partnerships. Ms. Wilber last served as the Executive Vice President, CMO, and Managing Director of Partnerships, EMEA, the highest position in the marketing department at
Disney, where she drove growth for Walt Disney Company’s marquee brands by leading marketing and communications for
Disney, Pixar, Star Wars, and Marvel. Additionally, she established and led EMEA’s 40-country integrated marketing, franchise and partnership functions, including a major reorganization of the EMEA channels to boost growth and profitability by significantly reducing expenses. She served as a Director for the board of
Euro Disney SCA, and served as a member of the board of directors of
Magical Cruise Company, more commonly known as
Disney Cruise Line. Ms. Wilber holds a Bachelor of Arts in History from
Brown University.

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.

Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore’s business prospects and clinical and product development plans (including with respect to enrollment in ongoing studies); its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments including online, e-commerce, direct-to-consumer channels, telehealth portal, and cash pay initiatives; the issuance of
U.S. and international patents providing expanded IP coverage; the possibility of future business models and revenue streams from the company’s potential use of nVNS for the acute treatment of PTSD, stroke and hemorrhagic brain injury, the potential of nVNS generally and gammaCore in particular and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the
SEC available at www.sec.gov.

For more information, visit www.electrocore.com.

Investors:
Rich Cockrell

CG Capital
404-736-3838
ecor@cg.capital
or
Media Contact:
Jackie Dorsky
electroCore
908-313-6331
Jackie.dorsky@electrocore.com

Release – Item 9 Labs Corp. Launches Reg A Public Offering Keep Cannabis Local Campaign

Posted on March 9, 2022 by Admin

Item 9 Labs Corp. Launches Reg A+ Public Offering & Keep Cannabis Local Campaign

Research, News, and Market Data on Item 9 Labs

Investors Now Have a Chance to Invest in the First Vertically Integrated U.S. Cannabis Franchise

PHOENIX, March 9, 2022 /PRNewswire/ — Item 9 Labs Corp. (OTCQX: INLB)–a vertically integrated cannabis dispensary franchisor and operator that produces premium, award-winning products–announced today the launch of its global, streamlined Regulation A, Tier 2 public offering for unaccredited and accredited investors. Now anyone can become a shareholder in Item 9 Labs Corp., which includes the national dispensary franchise, Unity Rd. and premium, award-winning cannabis brand Item 9 Labs. The Company is offering 28 million Units Each Comprised of One Share and One-Half of One Warrant. Upon the exercise of all warrants, the offering has maximum proceeds of $67.2 million.

With new states continuing to legalize cannabis, the industry is on track to explode – projecting $45 billion in revenue by 2025, a 50 percent increase from 2021*. As large players increasingly dominate the space, the business landscape will become even more challenging for new and independent entrepreneurs. The complexities of operating a cannabis business make it difficult for small, independent dispensaries to understand and stay on top of all the varying regulations and everyday challenges of managing and operating a compliant and successful dispensary.

The Company’s offering is set to accelerate the solution. Promoted under its “Keep Cannabis Local” campaign, this funding round offers the opportunity to invest in cannabis entrepreneurship, keeping the door to cannabis ownership open to industry newcomers and existing operators alike.

“Dispensary ownership is a lucrative opportunity, but it comes with a considerable amount of challenges to navigate,” said Item 9 Labs Corp.’s CEO Andrew Bowden. “The combination of our brands are the solution.”

Unity Rd. shops are rolling out state-by-state, community-by-community, and keeping dispensary ownership in the hands of local entrepreneurs nationwide. The franchise opportunity provides a viable opportunity for industry newcomers and small, locally owned and operated dispensaries to compliantly thrive, thanks to the robust backing and support of a national franchise. Unity Rd. offers direct access to the buying power, resources and supportive network normally reserved for multi-unit cannabis operators – empowering local, independents to confidently run their business.

“Unity Rd. offers one of the safest ways to enter the complex cannabis space with an experienced team guiding the path forward and supporting across all functions of the business,” Bowden added. “Franchising will propel the cannabis industry and keep business ownership in the hands of local owners.”

As the Unity Rd. franchise network expands nationally, the Company plans to bring Item 9 Labs products to the market through corporate development, acquisitions or partnerships with cultivation facilities in states where Unity Rd. franchise partners open cannabis retail shops. This strategic growth plan gives Unity Rd. operators front-of-the-line access to a reliable, award- winning product supply chain and offers the national product consistency that consumers have come to expect from franchises. This strategy also eases new market entry for Item 9 Labs products and creates unmatched market power across borders.

The Company encourages all interested investors to visit keepcannabislocal.com for a link to the Offering Circular and to learn how to invest in the offering. For more information on Item 9 Labs Corp. and its brands, visit item9labscorp.com. View the offering circular directly by clicking here.

For information about the Unity Rd. franchise opportunity, contact franchise@unityrd.com, call 720-923-5262 or visit unityrd.com.

About Item 9 Labs Corp.
Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The award-winning Item 9 Labs brand specializes in best-in-class products and user experience across several cannabis categories. The company also offers a unique dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. Item 9 Labs brings the best industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation. The veteran management team combines a diverse skill set with deep experience in the cannabis sector, franchising, and the capital markets to lead a new generation of public cannabis companies that provide transparency, consistency, and well-being. Headquartered in Arizona, the company is currently expanding its operations space by 640,000+ square feet on its 50-acre site, one of the largest properties in Arizona zoned to grow and cultivate flower. For additional information, visit item9labscorp.com.

About Unity Rd.
Unity Rd. is bridging the two previously disconnected worlds of cannabis and franchising. The industry trailblazer is the first to bring the cannabis dispensary franchise model to the United States—with duality of prowess in both industries to back it up. Built up from a collective 200 years in the legal cannabis industry and franchising, the company helps eager operators enter the complex industry with ease. The marijuana franchise pioneer offers its partners the knowledge, resources, and ongoing support needed to compliantly and successfully operate a dispensary. Launched in 2018, Unity Rd. has signed multiple agreements with nearly 20 entrepreneurial groups across the country. Recently, it was named one of the top cannabis retail leaders in the nation by MJBizDaily magazine and one of the “Best Cannabis Companies to Work For” in both the dispensary and cultivation categories in Cannabis Business Times’ elite 2020 list. The company is also the first cannabis business to earn a Franchise Times Dealmakers award. For more information, visit unityrd.com.

Forward-Looking Statement:
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

* https://mjbizdaily.com/new-marijuana-business-factbook-projects-nearly-45-billion-us-market- by-2025/

Media Contact:
Item 9 Labs Corp.
Jayne Levy, VP of Communications
Email: Jayne@item9labs.com

Investor Contact:
Item 9 Labs Corp.
Phone: 800-403-1140
Email: investors@item9labscorp.com

SOURCE Item 9 Labs Corp.

Item 9 Labs Corp. Launches Reg A+ Public Offering & Keep Cannabis Local Campaign

Posted on March 9, 2022 by Admin

Item 9 Labs Corp. Launches Reg A+ Public Offering & Keep Cannabis Local Campaign

Research, News, and Market Data on Item 9 Labs

Investors Now Have a Chance to Invest in the First Vertically Integrated U.S. Cannabis Franchise

For information about the Unity Rd. franchise opportunity, contact franchise@unityrd.com, call 720-923-5262 or visit unityrd.com.

* https://mjbizdaily.com/new-marijuana-business-factbook-projects-nearly-45-billion-us-market- by-2025/

Media Contact:
Item 9 Labs Corp.
Jayne Levy, VP of Communications
Email: Jayne@item9labs.com

Investor Contact:
Item 9 Labs Corp.
Phone: 800-403-1140
Email: investors@item9labscorp.com

SOURCE Item 9 Labs Corp.

Digital Currencies Gain Value on Biden Executive Order

Posted on March 9, 2022 by Admin

Further Optimism on Digital Currency Based on White House Order

Crypto participants believe a better-defined market is positive news for the asset class.

Digital assets’ potential benefits and the related technology usage are to get a “whole-of-government approach” according to an Executive Order signed by President Biden today (March 9). The Order outlines the U.S. policy for digital assets across six key priorities. The crypto market has reacted extremely positively with bitcoin (BTC) up over 20% since news of the order began circulating on Tuesday. Other cryptocurrencies like ethereum (ETH), and dogecoin (DOGE) have pushed higher as well.

The President’s six key priorities are: consumer and investor protection; financial stability; illicit finance; U.S. leadership in the global financial system and economic competitiveness; financial inclusion; and responsible innovation. Specific to each of these priorities, the order:

Explore a U.S. Central Bank
Digital Currency (CBDC) by placing urgency on research and development of a potential United States CBDC, should issuance be deemed in the national interest. The Order directs the U.S. Government to assess the technological infrastructure and capacity needs for a potential U.S. CBDC in a manner that protects Americans’ interests. The Order also encourages the Federal Reserve to continue its research, development, and assessment efforts for a U.S. CBDC, including development of a plan for broader U.S. Government action in support of their work. This effort prioritizes U.S. participation in multi-country experimentation and ensures U.S. leadership internationally to promote CBDC development that is consistent with U.S. priorities and democratic values.
Protect U.S. Consumers, Investors, and Businesses by directing the Department of the Treasury and other agency partners to assess and develop policy recommendations to address the implications of the growing digital asset sector and changes in financial markets for consumers, investors, businesses, and equitable economic growth. The Order also encourages regulators to ensure sufficient oversight and safeguard against any systemic financial risks posed by digital assets.
Protect U.S. and Global Financial Stability and Mitigate Systemic Risk by encouraging the Financial Stability Oversight Council to identify and mitigate economy-wide (i.e., systemic) financial risks posed by digital assets and to develop appropriate policy recommendations to address any regulatory gaps.
Mitigate the Illicit Finance
and National Security Risks Posed by the Illicit Use of Digital Assets by directing an unprecedented focus of coordinated action across all relevant U.S. Government agencies to mitigate these risks. It also directs agencies to work with our allies and partners to ensure international frameworks, capabilities, and partnerships are aligned and responsive to risks.
Promote U.S. Leadership in
Technology and Economic Competitiveness to Reinforce U.S. Leadership in
the Global Financial System by directing the Department of Commerce to work across the U.S. Government in establishing a framework to drive U.S. competitiveness and leadership in, and leveraging of digital asset technologies. This framework will serve as a foundation for agencies and integrate this as a priority into their policy, research and development, and operational approaches to digital assets.
Promote Equitable Access to Safe
and Affordable Financial Services by affirming the critical need for safe, affordable, and accessible financial services as a U.S. national interest that must inform our approach to digital asset innovation, including disparate impact risk. Such safe access is especially important for communities that have long had insufficient access to financial services. The Secretary of the Treasury, working with all relevant agencies, will produce a report on the future of money and payment systems, to include implications for economic growth, financial growth and inclusion, national security, and the extent to which technological innovation may influence that future.
Support Technological Advances
and Ensure Responsible Development and Use of Digital Assets by directing the U.S. Government to take concrete steps to study and support technological advances in the responsible development, design, and implementation of digital asset systems while prioritizing privacy, security, combating illicit exploitation, and reducing negative climate impacts.

Biden’s order asks the Justice Department to look at whether a new law is needed to create a new currency, with the Treasury, Securities and Exchange Commission, Federal Trade Commission, Consumer Financial Protection Commission and other agencies to study the impact on consumers. Although the Order uses words like ‘explore” and “potential” and provides financial market regulators a higher ability to place restrictions and reporting requirements on the asset class, it is a move forward that speculators in the crypto market have shown they believe further legitimizes current crypto.

Digital assets, including cryptocurrencies, have seen explosive growth in recent years, surpassing $3 trillion in circulation last November, up from $14 billion just five years prior. Around 16 percent of adult Americans – approximately 40 million people – have invested in, traded, or used cryptocurrencies. Over 100 countries are exploring or piloting Central Bank Digital Currencies (CBDCs) – digital forms of the country’s sovereign currency.

Suggested Reading

https://home.treasury.gov/news/press-releases/jy0644

Stay up to date. Follow us:

Category: